Pre-market hot trades in US stocks: Concerns over drug development risks lead to a pre-market plunge of 7.89% for Dermata Therapeutics

Pre-market Hot Trades in US Stocks Dermata is down 7.89% in pre-market trading. Based on recent key news: On December 30, Gerald Proehl, Chairman of Dermata Therapeutics, purchased 612,745 shares at an average price of $2.04 per share. This move is seen as a vote of confidence in the company's future development, driving the stock price up. On December 29, Dermata Therapeutics issued a statement regarding uncertainties in drug development, approval, and commercialization, warning investors of related risks. This may lead to market concerns about the company's prospects, affecting the stock price. On December 29, Dermata Therapeutics released the latest company information through the EDGAR system, highlighting risk factors in the drug development process, which may have heightened investor caution. The biotechnology sector has been volatile recently and requires attention. Top Gainers in Pre-market US Stocks Anghami is up 72.84% in pre-market trading. Based on recent key news: On December 31, Anghami reported financial performance for the first half of 2025, with revenue growth of 97%, reaching $48.4 million, primarily due to an increase in subscription users. Although profitability was impacted by investments supporting user growth, the company expects revenue to continue growing in the second half of the year. This news has driven the stock price up. Source: WSJ On December 31, Anghami reached a transformative agreement with Warner Bros. Discovery, further promoting the company's development. This agreement is seen as a key factor for future growth, enhancing market confidence. Source: Reuters On December 31, despite a 71.84% decline in stock price over the past 12 months, recent positive financial reports and strategic partnerships have led investors to adopt an optimistic outlook for the future, driving a rebound in stock price. Source: Benzinga The music streaming industry is becoming increasingly competitive, requiring attention to policy changes. ESH Acquisition is up 56.00% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Northann is up 50.93% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation